587289
Spartalizumab Biosimilar, Human PD-1
Size
£563.00
- SKU:
- 587289
- Purity:
- ≥95% (reducing SDS-PAGE, HPLC). Endotoxin: ≤1EU/mg (LAL)
- Storage Conditions:
- -20°C
- Supplier:
- United States Biological
- Host:
- Human
- Immunogen:
- Recombinant spartalizumab biosimilar produced in mammalian cells.
- Format:
- Supplied as a 0.2uM filtered solution, pH 7.4. No stabilizers or preservatives added.
- Extra Details:
- Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation. Applications: Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
- Shipping Conditions:
- Blue Ice